Literature DB >> 25858261

Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels.

Terry M Fredeking, Jorge E Zavala-Castro, Pedro González-Martínez, William Moguel-Rodríguez, Ernesto C Sanchez, Michael J Foster, Fredi A Diaz-Quijano1.   

Abstract

OBJECTIVE: To determine the effect of doxycycline treatment on cytokine levels, including tumor necrosis factor (TNF) and interleukin 6 (IL-6), and mortality in dengue patients at high risk of complication.
METHODS: A group of dengue hemorrhagic fever patients (n=231) were randomized to receive either standard supportive care or supportive care in addition to oral doxycycline twice daily for 7 days. Dengue virus infection was confirmed by PCR using multiple primers. Serum samples were obtained at days 0, 3, 5 and 7 and tested for levels of TNF and IL-6.
RESULTS: Doxycycline-treated group presented a 46% lower mortality than that observed in the untreated group (11.2% [13/116] vs 20.9% [24/115], respectively, p=0.05). Moreover, administration of doxycycline resulted in a significant (p<0.01) decrease in levels of TNF and IL-6 versus controls in the tests performed during follow-up (day 3, 5 and 7). Patients who died in both groups possessed significantly (p<0.01) higher levels of TNF and IL-6 compared to those who survived at all-time points.
CONCLUSION: The above findings suggest that doxycycline can provide a clinical benefit to dengue patients at high risk of complications. This effect could be mediated by decreasing pro-inflammatory cytokine levels.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25858261     DOI: 10.2174/1574891x10666150410153839

Source DB:  PubMed          Journal:  Recent Pat Antiinfect Drug Discov        ISSN: 1574-891X


  22 in total

1.  Case Management of Dengue: Lessons Learned.

Authors:  Siripen Kalayanarooj; Alan L Rothman; Anon Srikiatkhachorn
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

Review 2.  Repurposing of antibiotics for clinical management of COVID-19: a narrative review.

Authors:  Abdourahamane Yacouba; Ahmed Olowo-Okere; Ismaeel Yunusa
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-05-21       Impact factor: 3.944

Review 3.  Can tetracyclines ensure help in multiple sclerosis immunotherapy?

Authors:  Pedro Víctor-Carvalho; Rodolfo Thome; Catarina Rapôso
Journal:  J Clin Transl Res       Date:  2021-02-03

Review 4.  Important Role of the IL-32 Inflammatory Network in the Host Response against Viral Infection.

Authors:  Yaqin Zhou; Ying Zhu
Journal:  Viruses       Date:  2015-06-16       Impact factor: 5.048

5.  Doxycycline as a potential partner of COVID-19 therapies.

Authors:  Alexandre E Malek; Bruno P Granwehr; Dimitrios P Kontoyiannis
Journal:  IDCases       Date:  2020-06-06

6.  Doxycycline host-directed therapy in human pulmonary tuberculosis.

Authors:  Qing Hao Miow; Andres F Vallejo; Yu Wang; Jia Mei Hong; Chen Bai; Felicia Sw Teo; Alvin Dy Wang; Hong Rong Loh; Tuan Zea Tan; Ying Ding; Hoi Wah She; Suay Hong Gan; Nicholas I Paton; Josephine Lum; Alicia Tay; Cynthia Be Chee; Paul A Tambyah; Marta E Polak; Yee Tang Wang; Amit Singhal; Paul T Elkington; Jon S Friedland; Catherine Wm Ong
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 14.808

7.  Immunomodulatory Effect of Doxycycline Ameliorates Systemic and Pulmonary Inflammation in a Murine Polymicrobial Sepsis Model.

Authors:  Anasuya Patel; Hemant Khande; Hariharan Periasamy; Santosh Mokale
Journal:  Inflammation       Date:  2020-06       Impact factor: 4.092

Review 8.  Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.

Authors:  Paul A Yates; Steven A Newman; Lauren J Oshry; Robert H Glassman; Ashton M Leone; Elias Reichel
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

9.  Effect of non-surgical periodontal therapy on glycemic control of type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis.

Authors:  Ruoyan Cao; Qiulan Li; Qiqi Wu; Mianfeng Yao; Yu Chen; Hongbo Zhou
Journal:  BMC Oral Health       Date:  2019-08-06       Impact factor: 2.757

10.  A novel plan to deal with SARS-CoV-2 and COVID-19 disease.

Authors:  Raphael B Stricker; Melissa C Fesler
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.